Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYTHROCIN STEARATE.
ERYC vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic